{"created":"2023-06-19T10:43:35.048655+00:00","id":3825,"links":{},"metadata":{"_buckets":{"deposit":"16a73d95-014b-4c8d-9ab6-28c2aa5ce081"},"_deposit":{"created_by":11,"id":"3825","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3825"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003825","sets":["30:48:270"]},"author_link":["6500","8434","3187","393","2871","3334","6430","8435","3286","1873"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-02-22","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"10","bibliographicPageStart":"1","bibliographic_titles":[{},{"bibliographic_title":"Modern rheumatology","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"熊谷, 康佑"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"奥村, 法昭"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"天野, 泰孝"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"彌山, 峰史"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"三村, 朋大"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"前田, 勉"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"久保, 充彦"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"森, 幹士"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"今井, 晋二"}],"nameIdentifiers":[{},{},{}]}]},"item_4_description_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"pdf","subitem_description_type":"Other"}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives:\nElderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital. ","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nDemographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190). ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nThere was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA. ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nPatients with EORA may be able to achieve LDA with lower drug dosage than those with YORA. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Taylor and Francis Ltd."}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"33538619","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1080/14397595.2021.1883251"}],"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1080/14397595.2021.1883251","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1439-7609","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KUMAGAI, Kosuke"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"OKUMURA, Noriaki"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"AMANO, Yasutaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAYAMA, Takafumi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"MIMURA, Tomohiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MAEDA, Tsutomu"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"KUBO, Mitsuhiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MORI, Kanji"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Barrett-Jolley, Richard"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"IMAI, Shinji"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-02-22"}],"displaytype":"detail","filename":"14397595.2021.1883251.pdf","filesize":[{"value":"381.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"14397595.2021.1883251","url":"https://shiga-med.repo.nii.ac.jp/record/3825/files/14397595.2021.1883251.pdf"},"version_id":"ccf54f84-3f8a-4f38-ad35-50ce3392224f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Disease activity score 28-CRP","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"elderly-onset rheumatoid arthritis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"low disease activity","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"simplified disease activity index","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"young-onset rheumatoid arthritis","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity."}]},"item_type_id":"4","owner":"11","path":["270"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-03-29"},"publish_date":"2021-03-29","publish_status":"0","recid":"3825","relation_version_is_last":true,"title":["Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:37:21.906300+00:00"}